|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
260,040,000 |
Market
Cap: |
124.57(B) |
Last
Volume: |
808,470 |
Avg
Vol: |
1,608,675 |
52
Week Range: |
$332.58 - $485.53 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ-100 |
|
S&P 400 MIDCAP |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 543 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
40,257 |
161,595 |
276,622 |
637,091 |
Total Sell Value |
$18,057,339 |
$68,277,055 |
$109,821,201 |
$217,614,554 |
Total People Sold |
10 |
13 |
14 |
18 |
Total Sell Transactions |
14 |
47 |
70 |
137 |
End Date |
2024-03-14 |
2023-12-12 |
2023-06-13 |
2022-06-13 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Atkinson Edward Morrow Iii |
EVP, Chief Technical Ops. Off. |
|
2024-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
4,743 |
24,882 |
|
- |
|
Leiden Jeffrey M |
Executive Chairman |
|
2024-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
7,707 |
41,046 |
|
- |
|
Ambrose Kristen |
SVP & Chief Accounting Officer |
|
2024-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
1,853 |
11,641 |
|
- |
|
Tatsis Ourania |
EVP, Chief Reg. & Quality Off. |
|
2024-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
14,842 |
63,479 |
|
- |
|
Kewalramani Reshma |
CEO & President |
|
2024-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
41,488 |
150,199 |
|
- |
|
Wagner Charles F Jr |
EVP & Chief Financial Officer |
|
2024-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
15,254 |
58,947 |
|
- |
|
Bozic Carmen |
EVP and CMO |
|
2024-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
13,680 |
42,982 |
|
- |
|
Sachdev Amit |
EVP Chief Patient & Ext Af Off |
|
2024-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
13,680 |
72,494 |
|
- |
|
Altshuler David |
EVP, Global Research and CSO |
|
2024-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
13,680 |
45,718 |
|
- |
|
Arbuckle Stuart A |
EVP, COO |
|
2024-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
18,186 |
74,742 |
|
- |
|
Biller Jonathan |
EVP and Chief Legal Officer |
|
2024-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
6,294 |
16,863 |
|
- |
|
Atkinson Edward Morrow Iii |
EVP, Chief Technical Ops. Off. |
|
2024-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
6,260 |
20,139 |
|
- |
|
Leiden Jeffrey M |
Executive Chairman |
|
2024-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
30,916 |
33,339 |
|
- |
|
Ambrose Kristen |
SVP & Chief Accounting Officer |
|
2024-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
2,950 |
9,788 |
|
- |
|
Leiden Jeffrey M |
Executive Chairman |
|
2024-01-08 |
4 |
AS |
$419.07 |
$2,785,977 |
D/D |
(6,648) |
2,423 |
|
6% |
|
Wagner Charles F Jr |
EVP & Chief Financial Officer |
|
2024-01-02 |
4 |
AS |
$405.00 |
$1,215,000 |
D/D |
(3,000) |
43,693 |
|
5% |
|
Kewalramani Reshma |
CEO & President |
|
2023-12-15 |
4 |
AS |
$407.00 |
$6,973,945 |
D/D |
(17,135) |
108,711 |
|
-4% |
|
Kewalramani Reshma |
CEO & President |
|
2023-12-15 |
4 |
OE |
$155.57 |
$3,115,593 |
D/D |
17,135 |
125,846 |
|
- |
|
Leiden Jeffrey M |
Executive Chairman |
|
2023-12-13 |
4 |
AS |
$399.41 |
$5,333,799 |
D/D |
(13,354) |
9,071 |
|
-2% |
|
Arbuckle Stuart A |
EVP, COO |
|
2023-12-13 |
4 |
AS |
$399.00 |
$3,432,597 |
D/D |
(8,603) |
56,556 |
|
-2% |
|
Arbuckle Stuart A |
EVP, COO |
|
2023-12-13 |
4 |
OE |
$187.53 |
$1,613,321 |
D/D |
8,603 |
65,159 |
|
- |
|
Kewalramani Reshma |
CEO & President |
|
2023-12-13 |
4 |
AS |
$397.00 |
$2,023,906 |
D/D |
(5,098) |
108,711 |
|
-2% |
|
Thornberry Nancy |
Director |
|
2023-12-05 |
4 |
A |
$0.00 |
$0 |
D/D |
1,136 |
1,136 |
|
- |
|
Wagner Charles F Jr |
EVP & Chief Financial Officer |
|
2023-11-20 |
4 |
AS |
$349.88 |
$1,049,640 |
D/D |
(3,000) |
46,693 |
|
15% |
|
Sachdev Amit |
EVP Chief Patient & Ext Af Off |
|
2023-11-15 |
4 |
AS |
$369.92 |
$12,947 |
D/D |
(35) |
58,814 |
|
19% |
|
1777 Records found
|
|
Page 4 of 72 |
|
|